Longboard Pharmaceuticals Inc (NAS:LBPH)
$ 59.98 0.02 (0.03%) Market Cap: 2.34 Bil Enterprise Value: 2.06 Bil PE Ratio: 0 PB Ratio: 8.51 GF Score: 35/100

Q2 2024 Longboard Pharmaceuticals Inc Earnings Call and Discussion of Topline Phase 1 SAD Data for LP659 Transcript

Aug 01, 2024 / 08:30PM GMT
Release Date Price: $32.92 (-0.96%)
Operator

Good afternoon, ladies and gentlemen, and welcome to the Longboard Pharmaceutical earnings and incorporate update Call. As a reminder, this conference call is being recorded.

I would now like to turn the call over to Brandi Roberts, Longboard's Chief Financial Officer. You may begin.

Brandi Roberts
Longboard Pharmaceuticals Inc - Chief Financial Officer, Executive Vice President

Thank you, and good afternoon, everyone. Welcome to Longboard's conference call and webcast where we'll be providing a corporate update, including results from our LP659 single-ascending dose study.

Before we begin today, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company, including without limitation, statements about the potential of our product candidates, the anticipated timing and design of clinical trials, top line data, commercial opportunities and financial guidance. These statements are subject to risks and uncertainties that could cause actual results to differ.

Factors

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot